Current status and perspective of antiangiogenic therapy for cancer: urinary cancer.

International Journal of Clinical Oncology
Shigeru KandaHiroshi Kanetake

Abstract

Angiogenesis is considered a prerequisite for solid tumor growth. Antiangiogenic therapy reduces tumor size and extends host survival in a number of preclinical animal models. However, in humans antiangiogenic therapy is a poor promoter of tumor regression and has shown minimal effect on patient survival. In urinary cancers, such as renal cell cancer, prostate cancer, and bladder cancer, advanced refractory disease is a good candidate for antiangiogenic therapy because of its resistance to ordinary chemotherapy, radiotherapy, and hormonal therapy. Unique characteristics of molecular mechanisms underlie the induction of angiogenesis in urinary cancers. In this review, we summarize these unique mechanisms and review the results of clinical trials of antiangiogenic therapy for these cancers, discussing prospects and problems relating to antiangiogenic therapy.

References

Jan 1, 1979·European Urology·G ConcolinoU Bracci
Jun 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C MyersM M Uhrich
Mar 31, 1992·Biochemical and Biophysical Research Communications·J EguchiY Saito
Jan 3, 1990·Journal of the National Cancer Institute·J Folkman
Jun 1, 1990·The Journal of Urology·G L Morris, J G Dodd
Sep 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·C BetsholtzB Westermark
Jul 1, 1987·Journal of Cellular Physiology·R J CoffeyH L Moses
Feb 1, 1981·Proceedings of the National Academy of Sciences of the United States of America·J GrossJ Folkman
Nov 1, 1980·Urology·S C Jacobs, R K Lawson
Oct 1, 1994·British Journal of Urology·T MoritaA Tokue
Feb 28, 1995·Proceedings of the National Academy of Sciences of the United States of America·E C KohnL A Liotta
Apr 19, 1995·Journal of the National Cancer Institute·E E VoestJ Folkman
Jul 1, 1995·The Journal of Experimental Medicine·A L AngiolilloG Tosato
Nov 1, 1995·Journal of the National Cancer Institute·B H BochnerP W Nichols
Sep 1, 1993·The American Journal of Physiology·C M Van ItallieN J Siegel
May 1, 1994·Nature Genetics·J R GnarraF M Duh
Jun 1, 1993·The Journal of Experimental Medicine·A L MoreiraG Kaplan
Feb 20, 1996·International Journal of Cancer. Journal International Du Cancer·G StummR Waldherr
Feb 16, 1996·The Journal of Biological Chemistry·G Patstone, P Maher
Jun 21, 1996·International Journal of Cancer. Journal International Du Cancer·P G NataliM F Di Renzo
May 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E C KohnE Reed
Jun 10, 1997·Proceedings of the National Academy of Sciences of the United States of America·N SinC M Crews
May 1, 1998·The New England Journal of Medicine·R C Young
Nov 25, 1998·Proceedings of the National Academy of Sciences of the United States of America·Y CaoK Alitalo

❮ Previous
Next ❯

Citations

Jan 25, 2008·Cancer Immunology, Immunotherapy : CII·Jianping PanDieter Kabelitz
Apr 30, 2013·Asian Pacific Journal of Cancer Prevention : APJCP·Yu-Jing HuangYang Yao
Feb 8, 2020·Anti-cancer Agents in Medicinal Chemistry·Shi Zhou, Haijun Zhang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.